Hi Oxxa...doubt that there will be much in the way of tracking SAS pay per patient (SPPP) programs going forward. Focus and resources will be on main trials now. They have all the RWE they need and thus unlikely to record info from the SPPP.
In theory they would be obtaining additional quantities for those already on SAS program and requiring boosters but you'd have to verify that from treating Docs.
My views
PAR CEO explains SAS patient results in interview, page-23
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 20.0¢ | $201.6K | 994.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 429247 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 13806 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |